This CPB has been revised to state that leuprolide mesylate (Camcevi) is considered medically necessary for the treatment of advanced prostate cancer. This CPB has been revised: (i) for leuprolide acetate (subcutaneous injection), to add use as a "single agent" and "recurrent, unresectable" to the criteria for salivary gland tumors, (ii) for Lupron Depot (3.75 mg, 11.25 mg) removed malignant sex cord-stromal tumors as an indication since these strengths are not indicated in NCCN; and added use as a "single agent" and "persistent disease or recurrence" to the criteria for epithelial ovarian cancer, (iii) remove "acute intermittent porphyria" and "preservation (suppression) of ovarian function during chemotherapy" as experimental and investigational for Lupron Depot 3.75 mg or 3-month 11.25 mg therapy, and (iv) remove premature ovarian failure secondary to chemotherapy as experimental and investigational for Zoladex therapy. This CPB has been updated to: (i) add Camcevi as a more costly gonadotropin-releasing hormone agonist for the prostate cancer indication, (ii) separate the leuprolide acetate for depot suspension products to align with CVS/Caremark policy, (iii) add additional dosage and administration information, (iv) add Camcevi to list of products that require precertification, and (v) reorganize subheaders and content.